PDL BioPharma, Inc. Business Combination, Consideration Transferred
PDL BioPharma, Inc. reported Business Combination, Consideration Transferred of $1.20 million for the 0-month period ending 2018-01-08, per its 10-Q filed 2018-11-07.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Consideration Transferred and Preacquisition Equity Interest in Acquiree › Business Combination, Consideration Transferred
us-gaap:BusinessCombinationConsiderationTransferred1 · last filed 2020-06-29
- 2018-01-08: Business Combination, Consideration Transferred 0 month $1.20M.
- 2018-01-07: Business Combination, Consideration Transferred 0 month $1.20M.
- 2016-07-02: Business Combination, Consideration Transferred 0 month $244.30M; Business Combination, Consideration Transferred 0 month as first filed $244.31M.
| Period end | Business Combination, Consideration Transferred 0 month | Business Combination, Consideration Transferred 0 month as first filed |
|---|---|---|
| 2018-01-08 | $1.20M 10-Q · filed 2018-11-07 | |
| 2018-01-07 | $1.20M 8-K · filed 2020-06-29 | |
| 2016-07-02 | $244.30M 10-K · filed 2019-03-15 | $244.31M 10-Q · filed 2016-11-03 |